Novavax (NVAX) Research & Development (2016 - 2025)
Historic Research & Development for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $98.3 million.
- Novavax's Research & Development rose 1274.61% to $98.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.8 million, marking a year-over-year decrease of 1786.59%. This contributed to the annual value of $391.2 million for FY2024, which is 4696.03% down from last year.
- As of Q3 2025, Novavax's Research & Development stood at $98.3 million, which was up 1274.61% from $79.2 million recorded in Q2 2025.
- Over the past 5 years, Novavax's Research & Development peaked at $963.0 million during Q4 2021, and registered a low of $79.2 million during Q2 2025.
- In the last 5 years, Novavax's Research & Development had a median value of $219.5 million in 2023 and averaged $271.8 million.
- In the last 5 years, Novavax's Research & Development skyrocketed by 340796.69% in 2021 and then crashed by 7322.31% in 2022.
- Quarter analysis of 5 years shows Novavax's Research & Development stood at $963.0 million in 2021, then plummeted by 73.22% to $257.8 million in 2022, then tumbled by 36.13% to $164.7 million in 2023, then crashed by 36.62% to $104.4 million in 2024, then fell by 5.85% to $98.3 million in 2025.
- Its last three reported values are $98.3 million in Q3 2025, $79.2 million for Q2 2025, and $88.9 million during Q1 2025.